Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · IEX Real-Time Price · USD
491.57
+3.45 (0.71%)
At close: Jul 19, 2024, 4:00 PM
494.89
+3.32 (0.68%)
Pre-market: Jul 22, 2024, 7:31 AM EDT
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 5,400 employees as of December 31, 2023. The number of employees increased by 600 or 12.50% compared to the previous year.
Employees
5,400
Change (1Y)
600
Growth (1Y)
12.50%
Revenue / Employee
$1,886,111
Profits / Employee
$744,333
Market Cap
126.85B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Abbott Laboratories | 114,000 |
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Sanofi | 86,088 |
Boston Scientific | 48,000 |
Amgen | 26,700 |
Stryker | 26,700 |
VRTX News
- 6 days ago - Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum's TPD²® Technology to Develop Novel Degrader-Antibody Conjugates - Business Wire
- 19 days ago - Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis - Business Wire
- 20 days ago - Vertex to Announce Second Quarter 2024 Financial Results on August 1 - Business Wire
- 24 days ago - This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
- 4 weeks ago - Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions - Business Wire
- 5 weeks ago - Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress - Business Wire
- 5 weeks ago - Vertex Shares Rising on Expanded Therapy Offerings - FXEmpire
- 6 weeks ago - Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA® - Business Wire